LITTLE FALLS, NJ - July 17, 2012 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB: XDSL.OB) and Stevens Institute of Technology have announced an official agreement to jointly pursue business opportunities with government and industry as well as research and development (R&D) projects.

Specifically, Stevens and mPhase will collaborate on the design and fabrication of an advanced battery technology utilizing intellectual property and know-how from both parties with the possibility of integrating and advancing mPhase's Smart NanoBattery Technology with Stevens' graphene-based inkjet printing method for printing electrodes and electronic circuits.

1. The “D” Word

There is little love in the junior mining sector this AM. The Canadian venture exchange (TSXV) is close to a new three year low. The decline since March 2011 has been breathtaking. It is true that these “venture” companies are the most illiquid in terms of trading activity and those most in need of cash. As an overall case study of the economy we make the case that the TSXV decline (more than half the index value has evaporated over the past 16 months, down 30% in the last 4 months), is shouting deflation – at least the expectation of deflation.

Written by Michael A. Berry, Ph.D. - [ Discovery Investing Web Site ]

New York, NY, - July 16, 2012 – (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in renewable energy stock research for independent investors, issues an investor alert for BioFuel Energy Corp. (NasdaqCM :BIOF), trading up at $3.09, gaining   $0.60 or 24.29% as of  12:24PM EDT on over 244,000 shares.

The stock is rebounding following a loss in Friday’s trading session.

The most recent news from the company was late June  when it announced  a collaboration with   Gevo, Inc. (GEVO), a leading renewable chemicals and next-generation biofuels company, to explore high-volume production of isobutanol.

New York, New York - July 16, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Alnylam Pharmaceuticals, Inc. (NasdaqGS :ALNY), trading at $16.05, up $3.53 or 28.19%) as of 11:04AM EDT on over 2 Million shares. As of the time of this report, ALNY was the top percentage gainer on the NASDAQ.

The Company reported news today of the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR).